NASDAQ:MBIO Mustang Bio (MBIO) Stock Price, News & Analysis → The 1,000X Crypto Playbook (From True Market Insiders) (Ad) Free MBIO Stock Alerts $0.38 +0.04 (+10.92%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$0.33▼$0.3850-Day Range$0.37▼$1.3952-Week Range$0.33▼$8.17Volume379,775 shsAverage Volume173,908 shsMarket Capitalization$3.99 millionP/E RatioN/ADividend YieldN/APrice Target$17.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Mustang Bio alerts: Email Address Mustang Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside4,830.0% Upside$17.25 Price TargetShort InterestHealthy2.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMustang Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMustang Bio has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.35% of the float of Mustang Bio has been sold short.Short Interest Ratio / Days to CoverMustang Bio has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mustang Bio has recently decreased by 54.24%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMustang Bio does not currently pay a dividend.Dividend GrowthMustang Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBIO. Previous Next 2.4 News and Social Media Coverage News SentimentMustang Bio has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Mustang Bio this week, compared to 0 articles on an average week.Search Interest3 people have searched for MBIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mustang Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Mustang Bio is held by insiders.Percentage Held by InstitutionsOnly 9.95% of the stock of Mustang Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Mustang Bio is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mustang Bio is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMustang Bio has a P/B Ratio of 34.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe 1,000X Crypto PlaybookChris Rowe has created a “Crypto Playbook” that anyone can follow… potentially turning small investments into pers#1 Crypto for 2024, completely FREE. About Mustang Bio Stock (NASDAQ:MBIO)Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Read More MBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MBIO Stock News HeadlinesApril 16, 2024 | bizjournals.comBiotech cites federal review of deal with Chinese firm in latest staff cutsApril 15, 2024 | msn.comMustang Bio stock tumbles 27% amid news of mass layoffsApril 17, 2024 | True Market Insiders (Ad)The 1,000X Crypto PlaybookChris Rowe has created a “Crypto Playbook” that anyone can follow… potentially turning small investments into persApril 14, 2024 | investing.comMustang Bio announces major workforce reductionApril 12, 2024 | marketwatch.comMustang Bio to Cut Global Headcount by 81%March 28, 2024 | globenewswire.comMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesMarch 11, 2024 | globenewswire.comMustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 7, 2024 | tmcnet.comMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade GliomaApril 17, 2024 | True Market Insiders (Ad)The 1,000X Crypto PlaybookChris Rowe has created a “Crypto Playbook” that anyone can follow… potentially turning small investments into persMarch 7, 2024 | markets.businessinsider.comWhy Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving PremarketMarch 7, 2024 | globenewswire.comMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaFebruary 13, 2024 | uk.investing.comMustang Bio Inc (MBIO)January 11, 2024 | finance.yahoo.comMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceJanuary 6, 2024 | morningstar.comMustang Bio Inc MBIODecember 27, 2023 | benzinga.comMustang Bio Stock (NASDAQ:MBIO) Dividends: History, Yield and DatesDecember 22, 2023 | seekingalpha.comMBIO Mustang Bio, Inc.December 12, 2023 | msn.comMustang Bio files to sell 2.74M shares of common stock for holdersNovember 15, 2023 | markets.businessinsider.comMustang Bio’s Positive Financial Performance and Promising Clinical Developments Drive Buy RatingNovember 15, 2023 | finanznachrichten.deMustang Bio, Inc.: Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNovember 2, 2023 | finance.yahoo.comMustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingOctober 30, 2023 | finance.yahoo.comMustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesOctober 26, 2023 | marketwatch.comMustang Bio Shares Rise 13% After FDA Acceptance of IND ApplicationOctober 26, 2023 | finance.yahoo.comMustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade AstrocytomaAugust 25, 2023 | nasdaq.comCantor Fitzgerald Reiterates Mustang Bio (MBIO) Overweight RecommendationAugust 15, 2023 | finanznachrichten.deMustang Bio, Inc.: Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsAugust 15, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Mustang BioAugust 15, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Mustang Bio (MBIO)See More Headlines Receive MBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today4/17/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MBIO CUSIPN/A CIK1680048 Webwww.mustangbio.com Phone(781) 652-4500FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$17.25 High Stock Price Target$25.00 Low Stock Price Target$10.00 Potential Upside/Downside+4,392.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($6.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-433.08% Return on Assets-146.39% Debt Debt-to-Equity RatioN/A Current Ratio0.74 Quick Ratio0.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book38.40Miscellaneous Outstanding Shares10,390,000Free Float10,172,000Market Cap$3.99 million OptionableNot Optionable Beta1.58 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael S. Weiss Esq. (Age 58)Executive Chairman Comp: $60kDr. Manuel Litchman M.D. (Age 70)President, CEO & Director Comp: $480.79kMr. James B. Murphy (Age 67)Interim Chief Financial Officer Mr. Peter Carney (Age 37)Controller & Interim Chief Accounting Officer Mr. Matthew Wein J.D.VP & General CounselMs. Debra Manning SPHRSenior VP & Head of Human ResourcesMs. Lynn E. Bayless M.S.VP & Head of Regulatory AffairsDr. Bruce Dezube M.D.Senior VP & Head of Clinical DevelopmentMr. Greg Furrow M.S.Chief Quality OfficerMr. Richard Bodmer M.S.Head of CMC DevelopmentMore ExecutivesKey CompetitorsNexImmuneNASDAQ:NEXIEvoke PharmaNASDAQ:EVOKCingulateNASDAQ:CINGVirpax PharmaceuticalsNASDAQ:VRPXBiophytisNASDAQ:BPTSView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 435,764 shares on 2/13/2024Ownership: 4.726%View All Institutional Transactions MBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Mustang Bio stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBIO shares. View MBIO analyst ratings or view top-rated stocks. What is Mustang Bio's stock price target for 2024? 3 equities research analysts have issued 12 month price targets for Mustang Bio's shares. Their MBIO share price targets range from $10.00 to $25.00. On average, they anticipate the company's stock price to reach $17.25 in the next year. This suggests a possible upside of 4,830.0% from the stock's current price. View analysts price targets for MBIO or view top-rated stocks among Wall Street analysts. How have MBIO shares performed in 2024? Mustang Bio's stock was trading at $1.35 at the beginning of the year. Since then, MBIO shares have decreased by 74.1% and is now trading at $0.3499. View the best growth stocks for 2024 here. Are investors shorting Mustang Bio? Mustang Bio saw a drop in short interest in March. As of March 31st, there was short interest totaling 178,000 shares, a drop of 54.2% from the March 15th total of 389,000 shares. Based on an average daily trading volume, of 154,600 shares, the short-interest ratio is presently 1.2 days. Currently, 2.4% of the shares of the company are sold short. View Mustang Bio's Short Interest. When is Mustang Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our MBIO earnings forecast. How were Mustang Bio's earnings last quarter? Mustang Bio, Inc. (NASDAQ:MBIO) posted its earnings results on Monday, March, 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.68) by $0.97. When did Mustang Bio's stock split? Mustang Bio shares reverse split before market open on Tuesday, April 4th 2023. The 1-15 reverse split was announced on Tuesday, April 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Mustang Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu BioPharma (AYTU) and Kadmon (KDMN). How do I buy shares of Mustang Bio? Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MBIO) was last updated on 4/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe 1,000X Crypto PlaybookTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchIRS Loophole Gives Americans An Escape From InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.